rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jake Bauer

Director

Company insider

Files Form 4 as: Director, BridgeBio Oncology Therapeutics; Director, Immunovant; Director, Enliven Therapeutics; Chief Business Officer, MyoKardia.

Every Form 4 they filed

In numbers

Trades disclosed
95
Buys
0
Sells
18
Bought
$0
Sold
$6.6M
Companies
4
Companies where not an officer
3
First trade
2 Feb 2016
Last trade
16 Jun 2026
Last filed
18 Jun 2026

Companies traded

Where they are an officer
MyoKardiaOfficer · last 17 Nov 20200 buys · 18 sells
Everywhere else they filed: board seats, 10% stakes, other companies
BBOT BridgeBio Oncology TherapeuticsDirector · Biotechnology · last 16 Jun 20260 buys · 0 sells
IMVT ImmunovantDirector · Biotechnology · last 7 Apr 20260 buys · 0 sells
ELVN Enliven TherapeuticsDirector · Biotechnology · last 12 Feb 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jun 2026filed 18 Jun 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—31,675 at $0.00filing
16 Jun 2026filed 18 Jun 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—31,675 at $0.00filing
7 Apr 2026filed 9 Apr 2026IMVT ImmunovantBiotechnologySEC FORM 4 Code A—13,880 at $0.00filing
7 Apr 2026filed 9 Apr 2026IMVT Immunovantoption or derivative · BiotechnologySEC FORM 4 Code A—7,061 at $0.00filing
7 Apr 2026filed 9 Apr 2026IMVT Immunovantoption or derivative · BiotechnologySEC FORM 4 Code A—7,061 at $0.00filing
7 Apr 2026filed 9 Apr 2026IMVT ImmunovantBiotechnologySEC FORM 4 Code A—13,880 at $0.00filing
12 Feb 2026filed 17 Feb 2026ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—17,126 at $0.00filing
12 Feb 2026filed 17 Feb 2026ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—17,126 at $0.00filing
26 Aug 2025filed 28 Aug 2025BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—138,193 at $0.00filing
1 May 2025filed 5 May 2025IMVT Immunovantoption or derivative · BiotechnologySEC FORM 4 Code A—35,234 at $0.00filing
1 May 2025filed 5 May 2025IMVT ImmunovantBiotechnologySEC FORM 4 Code A—25,016 at $0.00filing
6 Feb 2025filed 10 Feb 2025ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,491 at $0.00filing
13 Feb 2024filed 20 Feb 2024ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—23,364 at $0.00filing
13 Feb 2024filed 15 Feb 2024ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—16,835 at $0.00filing
23 Feb 2023filed 6 Apr 2023ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—27,567 at $0.00filing
23 Feb 2023filed 27 Feb 2023ELVN Enliven Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—17,706 at $0.00filing
23 Feb 2023filed 27 Feb 2023ELVN Enliven TherapeuticsBiotechnologySEC FORM 4 Code A—87,372filing
17 Nov 2020filed 19 Nov 2020MyoKardiaoption or derivativeSEC FORM 4 Code D—16,530filing
17 Nov 2020filed 19 Nov 2020MyoKardiaoption or derivativeSEC FORM 4 Code D—8,748filing
17 Nov 2020filed 19 Nov 2020MyoKardiaoption or derivativeSEC FORM 4 Code D—35,150filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed18

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.